though the antibiotic exhibits weak growth inhibitory activity for cultured K562 cells (IC50, 50% growth-inhibitory concentration is more than 25^g/ml), it strongly potentiates cytotoxicity of 1 -^-D-arabinofuranosylcytosine (Ara-C) against K562 cells by increasing cellular uptake of Ara-C and formation of Ara-C nucleotides4).
In this communication, we examined the potentiation activity of cadeguomycin on cytotoxicity of other pyrimidine nucleoside analogs which exhibit antitumor activity.
As seen in Fig. 1 Table 1 . Activity of Ara-C was greatly potentiated by cadeguomycin as previously reported4) and those of 5-azadeoxycytidine and 5-azacytidine were also enhanced by the antibiotic at 1^g/ml, although the potentiation ratios were less than that of FCdR. On the contrary, 5-fluorodeoxyuridine (FUdR), 3-* To whomrequests for reprints should be addressed. deoxyuridine, UR : uridine, Ura : uracil.
deazauridine and 5-fluorouracil (5-FU) were not potentiated, suggesting that the potentiation activity of cadeguomycin is restricted to cytidine and deoxycytidine analogs.
Recently, we have found that the dCMP deaminase activity in K562 cells was greatly decreased by cadeguomycin treatment. This enzymeconverts dCMP to dUMP and also inactivates Ara-C by converting Ara-CMP to Ara-UMP. Thus, the potentiation of the cytotoxicity of cytidine and deoxycytidine analogs by cadeguomycin seems to be due to inhibition of inactivation of these analogs. Ara-C might be the best substrate for the enzyme among the cytidine and deoxycytidine analogs tested here. FCdR is more active than 5-FU and FUdR against certain experimental tumors5), and is believed to exert its cytotoxicity mainly by inhibiting thymidylate synthetase after conversion to FdUMP6), like 5-FU and FUdR. However, our results that cadeguomycin potentiates the activity of FCdR and not 5-FU and FUdR, suggest that FCdR exerts its cytotoxicity by formation of FCdR nucleotides rather than conversion to uridine base by deamination, and they support the concept that FCdR is incorporated into DNA after phosphorylated to FdCTP70. Cadeguomycin is shown to be useful for potentiation of the cytotoxicity of not only Ara-C but also other antitumor substances of cytidine and deoxycytidine analog in vitro. We are now trying combination therapy of cadeguomycin and Ara-C or these analogs in experimental tumors in vivo.
